Standardised immunophenotypic analysis of myeloperoxidase in acute leukaemia.
Anne E BrasZgjim OsmaniValerie de HaasMojca Jongen-LavrencicJeroen G Te MarveldeC Michel ZwaanEster MejstrikovaPaula FernandezTomasz SzczepanskiAlberto OrfaoJacques J M van DongenVincent H J van der VeldenPublished in: British journal of haematology (2020)
Given its myeloid-restricted expression, myeloperoxidase (MPO) is typically used for lineage assignment (myeloid vs. lymphoid) during acute leukaemia (AL) diagnostics. In the present study, a robust flow cytometric definition for MPO positivity was established based on the standardised EuroFlow protocols, the standardised Acute Leukaemia Orientation Tube and 1734 multicentre AL cases (with confirmed assay stability). The best diagnostic performance was achieved by defining MPO positivity as ≥20% of the AL cells exceeding a lymphocyte-based threshold. The methodology employed should be applicable to any form of standardised flow cytometry.
Keyphrases
- liver failure
- respiratory failure
- flow cytometry
- drug induced
- aortic dissection
- bone marrow
- acute myeloid leukemia
- induced apoptosis
- poor prognosis
- clinical trial
- randomized controlled trial
- high throughput
- hepatitis b virus
- intensive care unit
- study protocol
- single cell
- signaling pathway
- cell death
- endoplasmic reticulum stress
- immune response